Larimar Therapeutics, Inc. logo

LRMR Earnings Date: Nov 5, 2026 (Estimated) — Larimar Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology

Updated

Price $2.55
Market Cap $264.9M
P/E -1.0
52W Range $1.92 – $6.42
Next Earnings (est.)

When is LRMR's next earnings date?

Larimar Therapeutics, Inc. (LRMR) is expected to report earnings on Thursday, November 5, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.35.

How did LRMR do in its last earnings report?

In its most recent report on Aug 4, 2026 (Q2 2026), Larimar Therapeutics, Inc. posted EPS of -$0.30 versus the -$0.38 estimate, a beat of 21.1%. Revenue was $0. The stock's 1-day post-earnings move was +3.3%.

How much does LRMR stock move after earnings?

LRMR beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.7% (up or down) in the day after earnings.

About Larimar Therapeutics, Inc.

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

Earnings History

DatePeriodEPS Est.EPS Act.SurpriseRevenueResult1D Δ1W Δ1M Δ
2026-08-04Q2 2026-0.38-0.30+21.05%$0✅ Beat+3.27%+0.75%-1.00%
2026-05-14Q1 2026-0.56-0.31+44.64%$0✅ Beat-5.12%-13.90%-15.37%
2026-03-19Q4 2025-0.50-0.73-46.00%$0❌ Miss+3.95%+8.84%+11.63%
2025-11-05Q3 2025-0.41-0.61-48.78%$0❌ Miss-15.26%-4.47%-3.16%
2025-08-14Q2 2025-0.48-0.41+14.58%$0✅ Beat+14.52%+1.34%+5.65%
2025-04-30Q1 2025-0.41-0.46-12.20%$0❌ Miss+10.88%-12.13%-3.77%
2025-03-24Q4 2024-0.32-0.45-40.62%$0❌ Miss-10.24%-7.48%-6.30%
2024-08-07Q2 2024-0.30-0.34-13.33%$0❌ Miss-6.54%-1.05%+16.34%

Showing last 8 quarters.

Related Companies

Learn More

Explore More

Financial data from licensed market-data providers; risk factors from SEC EDGAR filings. AI-powered analysis. Data last updated .